---
figid: PMC7685213__bloodBLD2020007968Cf1
figtitle: Simple Rx for congenital erythropoietic porphyria
organisms:
- NA
pmcid: PMC7685213
filename: bloodBLD2020007968Cf1.jpg
figlink: pmc/articles/PMC7685213/figure/FU1/
number: F1
caption: Heme synthesis and use. The heme synthetic pathway and heme’s intracellular
  trafficking are diagrammed. The first and rate-limiting step is catalyzed by ALAS.
  ALAS2 is the erythroid-specific ALAS isoform (red). The presence of an iron responsive
  element (IRE) in the 5′ untranslated region of ALAS2 mRNA renders it exquisitely
  sensitive to iron. All other cells, including hepatocytes, contain ALAS1 (blue).
  CEP results from mutation of UROS, the fourth enzyme of the heme synthetic pathway.
  Other porphyrias result from mutations of other heme synthetic pathway enzymes,
  eg, HMBS (hydroxymethylbilane synthase; acute intermittent porphyria), UROD (uroporphyrinogen
  decarboxylase; porphyria cutanea tarda), CPOX (coproporphyrinogen oxidase; hereditary
  coproporphyria), PPOX (protoporphyrinogen oxidase; variegate porphyria), and FECH
  (ferrochelatase; erythropoietic protoporphyria). Iron chelation ameliorates CEP
  by reducing ALAS2 translation, thus decreasing heme synthesis and the buildup of
  pathway intermediates proximal to UROS and their phototoxic metabolites. ER, endoplasmic
  reticulum; Hgb, hemoglobin. Professional illustration by Patrick Lane, ScEYEnce
  Studios.
papertitle: A simple Rx for congenital erythropoietic porphyria.
reftext: Janis L. Abkowitz. Blood. 2020 Nov 19;136(21):2371-2372.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9442465
figid_alias: PMC7685213__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC7685213__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7685213__bloodBLD2020007968Cf1.html
  '@type': Dataset
  description: Heme synthesis and use. The heme synthetic pathway and heme’s intracellular
    trafficking are diagrammed. The first and rate-limiting step is catalyzed by ALAS.
    ALAS2 is the erythroid-specific ALAS isoform (red). The presence of an iron responsive
    element (IRE) in the 5′ untranslated region of ALAS2 mRNA renders it exquisitely
    sensitive to iron. All other cells, including hepatocytes, contain ALAS1 (blue).
    CEP results from mutation of UROS, the fourth enzyme of the heme synthetic pathway.
    Other porphyrias result from mutations of other heme synthetic pathway enzymes,
    eg, HMBS (hydroxymethylbilane synthase; acute intermittent porphyria), UROD (uroporphyrinogen
    decarboxylase; porphyria cutanea tarda), CPOX (coproporphyrinogen oxidase; hereditary
    coproporphyria), PPOX (protoporphyrinogen oxidase; variegate porphyria), and FECH
    (ferrochelatase; erythropoietic protoporphyria). Iron chelation ameliorates CEP
    by reducing ALAS2 translation, thus decreasing heme synthesis and the buildup
    of pathway intermediates proximal to UROS and their phototoxic metabolites. ER,
    endoplasmic reticulum; Hgb, hemoglobin. Professional illustration by Patrick Lane,
    ScEYEnce Studios.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ALAS1
  - ALAS2
  - HMBS
  - UROS
  - PPOX
  - HCRT
  - FECH
  - UROD
  - CPOX
  - CYGB
  - Glycine
  - succinyl
  - ALA
---
